BackPharming Group N.V. Overview

Pharming Group N.V. Intangible Assets

Pharming Group N.V.'s intangible assets is $130M.

Get informed when a big investor buys or sells

+ Follow
Intangible Assets
$130.99M

Peer average

Loading

Pharming Group N.V. Intangible Assets History

Loading

Pharming Group N.V. vs. peers: Intangible Assets Comparison

Loading

Pharming Group N.V. Intangible Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Pharming Group N.V. (PHAR) FAQ

Pharming Group N.V. (PHAR) currently reports a intangible assets of $130M as of March 2026. In the prior-year period, the figure was $0. Use the charts on this page to explore Pharming Group N.V.'s intangible assets history and peer comparisons.

Pharming Group N.V.'s intangible assets changed from $0 to $130M (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Pharming Group N.V. reported $130M in intangible assets as of March 2026. In the prior-year period, the figure was $0. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current intangible assets of $130M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Pharming Group N.V., and consider following PHAR for alerts when major investors trade the stock.

Pharming Group N.V. is classified in the Healthcare sector. On intangible assets, it currently shows $130M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing PHAR with unrelated industries.